CA
NZ
UK
AU
IND
US
• HeartSciences awarded an executive 425,000 restricted shares under its 2023 equity plan as a merger retention incentive.
• The equity plan was amended to add 6,000,000 authorized shares, bringing the total to 8,644,887.
• Microbot Medical (NASDAQ: MBOT) enters manufacturing agreement with Sanmina to expand LIBERTY® Endovascular Robotic System production.
• Moleculin Biotech reported favorable early efficacy signals for Annamycin in its MIRACLE trial for a high-risk leukemia subgroup.
• The financing stemmed from the conversion of 1.36 million warrants into shares.
• InflaRx (IFRX) is a clinical-stage biotechnology company focused on therapies targeting inflammation-related conditions.
• ChemoCentryx (CCXI) is a biotechnology company associated with therapies targeting inflammatory and autoimmune-related conditions.
• Jyong Biotech has attracted renewed market attention, with some observers asking whether healthcare speculation is helping drive recent moves.
• Perspective Therapeutics has drawn renewed market interest amid growing attention to the radiopharmaceutical field.
• Alaunos Therapeutics (Ticker: TCRT) has attracted renewed attention as a clinical-stage cell-therapy company.
Please wait processing your request...